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Rett Syndrome (RTT) is a neurodevelopmental 
disorder solely affecting females, and is caused by 
genetic mutations in the methyl CpG binding protein 
2 (MeCP2) gene. The MeCP2 gene produces the 
MeCP2 protein, which has many diverse functions 
including regulating the brain-derived neurotrophic 
factor (BDNF) gene, which produces the BDNF 
protein. Individuals with RTT have mutated MeCP2 
genes, which results in low levels of MeCP2 protein 
and BNDF protein. 
  
Regardless of these genetic mutations, individuals 
with RTT develop normally until about six to eight 
months of age. After this developmental window, 
neurological differences become present which are 
followed by phenotypic differences during which 
motor skills, language skills and social skills are 
impaired. In addition to these impairments, 
individuals with RTT also experience other 
symptoms such as breathing problems, sleep apnea 
and seizures. Seizures are a common symptom 
associated with RTT, as up to eighty percent of 
individuals with RTT experience seizures. 
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The use of AEDs is very common for females with 
RTT who experience seizures. However, due to the 
number of side effects associated with AEDs, they 
are not readily available or desirable for all females 
with RTT. Focusing research on treatments that will 
halt or prevent the seizures from occurring rather 
than treating the seizures as they appear will prove 
to be more beneficial. Two such treatments in 
consideration are increasing the amount of the 
BDNF protein as well as increasing the MeCP2 
protein present in the brain. Previous research in 
mice has shown that increasing the levels of these 
two proteins alleviates RTT-like symptoms. 
However, additional research must be done in order 
to implement these treatments effectively on a 
widespread scale. These treatments also have the 
potent ia l to be administered dur ing the 
developmental window in which neurological 
changes are present but phenotypic changes 
associated with RTT are not. Treating females with 
RTT who also experience seizures during this 
developmental window can potentially halt 
symptoms from appearing or help curb symptoms 
at an earlier stage in the lives of these individuals. 
Seizures are of a major concern for individuals with 
RTT because they are fairly common and make life 
much more difficult for these females. A female with 
RTT has a 5-38% chance of developing epilepsy 
and experiencing seizures as opposed to a 1-2% 
chance in regular individuals. Some individuals 
experience seizures in childhood, some in puberty 
and some others well into adulthood. Thus seizures 
can occur at any age, but the frequency of seizures 
has been found to decrease significantly after the 
age of twenty.  
  
Currently, the most commonly used medication is 
anti-epileptic drugs (AEDs). For individuals who 
have milder seizures, only one AED is prescribed. In 
other words a monotherapy strategy is used. For 
individuals who have other complications or more 
severe forms of seizures, a polytherapy approach is 
used where two or more AEDs are used in 
combination. AEDs, however, come with many side 
effects. For example, AEDs used in monotherapy or 
polytherapy can reduce vitamin D levels thereby 
increasing that individual’s risk for fractures.  
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